These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37011338)

  • 21. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
    Gillessen S; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Chi KN; Clarke N; Davis ID; de Bono J; Drake CG; Duran I; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Heinrich D; Higano CTS; Hofman MS; Hussain M; James N; Kanesvaran R; Kantoff P; Khauli RB; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Reiter RE; Roach M; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Small E; Smith M; Soule H; Sternberg CN; Steuber T; Suzuki H; Sweeney C; Sydes MR; Taplin ME; Tombal B; Türkeri L; van Oort I; Zapatero A; Omlin A
    Eur Urol; 2020 Apr; 77(4):508-547. PubMed ID: 32001144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline.
    Trabulsi EJ; Rumble RB; Jadvar H; Hope T; Pomper M; Turkbey B; Rosenkrantz AB; Verma S; Margolis DJ; Froemming A; Oto A; Purysko A; Milowsky MI; Schlemmer HP; Eiber M; Morris MJ; Choyke PL; Padhani A; Oldan J; Fanti S; Jain S; Pinto PA; Keegan KA; Porter CR; Coleman JA; Bauman GS; Jani AB; Kamradt JM; Sholes W; Vargas HA
    J Clin Oncol; 2020 Jun; 38(17):1963-1996. PubMed ID: 31940221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Cornford P; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; der Kwast THV; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; der Poel HGV; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Mottet N
    Eur Urol; 2021 Feb; 79(2):263-282. PubMed ID: 33039206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.
    Sandler HM; Eisenberger MA
    J Urol; 2007 Sep; 178(3 Pt 2):S20-4. PubMed ID: 17644123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline.
    Saylor PJ; Rumble RB; Tagawa S; Eastham JA; Finelli A; Reddy PS; Kungel TM; Nissenberg MG; Michalski JM
    J Clin Oncol; 2020 May; 38(15):1736-1743. PubMed ID: 31990618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?
    Bagcioglu M; Surcel C; Ozcan S; Mirvald C; Karagoz MA; Karadag MA; Huri E; Sarica K
    Arch Ital Urol Androl; 2017 Dec; 89(4):282-286. PubMed ID: 29473373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of locally advanced prostate cancer: new definitions and strategies.
    Roach M
    West J Med; 1998 Nov; 169(5):290-1. PubMed ID: 9830363
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of the pathologist in diagnosing prostate cancer and guiding therapy.
    Weinstein MH
    N C Med J; 2006; 67(2):140-5. PubMed ID: 16752719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
    Basch EM; Somerfield MR; Beer TM; Carducci MA; Higano CS; Hussain MH; Scher HI;
    J Clin Oncol; 2007 Nov; 25(33):5313-8. PubMed ID: 17925542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic prostate cancer: complications and treatment.
    McMurtry CT; McMurtry JM
    J Am Geriatr Soc; 2003 Aug; 51(8):1136-42. PubMed ID: 12890079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma.
    Sakai H; Yogi Y; Minami Y; Yushita Y; Kanetake H; Saito Y
    J Urol; 1993 May; 149(5):1020-3. PubMed ID: 7683340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic prostate cancer with normal level of serum prostate-specific antigen.
    Nishio R; Furuya Y; Nagakawa O; Fuse H
    Int Urol Nephrol; 2003; 35(2):189-92. PubMed ID: 15072491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expectant management of localized prostate cancer--who, what, when, where and how?
    Ehdaie B
    J Urol; 2012 Sep; 188(3):696-7. PubMed ID: 22818346
    [No Abstract]   [Full Text] [Related]  

  • 35. Re: Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
    Taneja SS
    J Urol; 2015 Jan; 193(1):128-9. PubMed ID: 25523659
    [No Abstract]   [Full Text] [Related]  

  • 36. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A; Simşek F; Ilker Y; Türkeri L; Ercan H
    Int Urol Nephrol; 1993; 25(3):271-8. PubMed ID: 7693607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
    Mukherji D; Youssef B; Dagher C; El-Hajj A; Nasr R; Geara F; Rabah D; Al Dousari S; Said R; Ashou R; Wazzan W; Jabbour M; Farha G; Al Hamdani N; Al Hallaq Y; Ghazal H; Dbouk H; Bachir B; El Khoury C; Sakr G; Hussain HK; Sayyid K; Ibrahim K; Haidar M; Zouain N; Bitar N; Alameh W; Abbas F; Faddoul S; Nemer E; Assaf G; Farhat F; Bulbul M; Temraz S; Shamseddine A; Gillessen S; Omlin A; Khauli R
    World J Urol; 2020 Mar; 38(3):681-693. PubMed ID: 31297628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. More information on prostate specific antigen and prostate cancer.
    Stamey TA
    J Urol; 2003 Aug; 170(2 Pt 1):457-8. PubMed ID: 12853798
    [No Abstract]   [Full Text] [Related]  

  • 39. ACR Appropriateness Criteria
    ; Froemming AT; Verma S; Eberhardt SC; Oto A; Alexander LF; Allen BC; Coakley FV; Davis BJ; Fulgham PF; Hosseinzadeh K; Porter C; Sahni VA; Schuster DM; Showalter TN; Venkatesan AM; Wang CL; Remer EM
    J Am Coll Radiol; 2018 May; 15(5S):S132-S149. PubMed ID: 29724417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress in management of low-risk prostate cancer: how registries may change the world.
    Cooperberg MR
    Eur Urol; 2015 Jan; 67(1):51-52. PubMed ID: 25242556
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.